Statin therapy to protect heart health during melanoma treatment
Treatments studied
Part of Cancer, Heart & circulation, Skin clinical trials.
This trial tests whether taking a statin (a cholesterol-lowering medicine) during immunotherapy for melanoma can prevent heart problems. It may help protect your blood vessels while you receive cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with melanoma and are scheduled to start immunotherapy (nivolumab, pembrolizumab, or a combination with ipilimumab).
- You have some hardening of the arteries (atherosclerosis) in your aorta, which will be checked with an imaging test.
- You are not currently taking statins and have never had a bad reaction to them.
- You do not have severe liver or kidney disease, and you are not taking certain medicines that could interact with statins.
- You are not pregnant or breastfeeding, and you do not have a history of alcohol or drug abuse within the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
This trial tests whether taking a daily statin (a cholesterol-lowering medicine) can reduce the harmful effects of breathing in bushfire smoke on your heart and lungs. It might help people who are generally healthy but exposed to smoky air.
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
This Phase 3 study tests whether taking atorvastatin (a cholesterol-lowering medicine) can improve outcomes for women with estrogen-receptor–positive breast cancer. It may help by affecting cancer-related pathways and reducing risk of recurrence or progression.
This trial tests whether adding a common cholesterol-lowering drug (a statin) to standard chemotherapy before surgery can improve outcomes for people with esophageal or gastroesophageal junction cancer. The goal is to see if the statin helps shrink the tumor and reduces the chance of the cancer coming back.
This trial tests whether common heart medicines (statins or ACE-inhibitors) can protect the heart during cancer radiation therapy. It is for adults who are about to start chest radiation and have not taken these drugs before.
Hear when a new Atherosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.